Trial Profile
Phase I trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer pretreated by anthracycline and taxane
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Sep 2015
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 23 Jan 2013 New trial record